AML multi-gene panel testing: A review and comparison of two gene panels

Research paper by G. Thakral, K. Vierkoetter, S. Namiki, S. Lawicki, X. Fernandez, K. Ige, W. Kawahara, C. Lum

Indexed on: 18 Mar '16Published on: 03 Mar '16Published in: Pathology - Research and Practice


Risk adapted therapy is standard practice in Acute Myeloid Leukemia (AML). A common diagnostic approach involves focusing on a three gene panel (CEPBA, FLT3, and NPM1). However, a complete representation of prognostic and predictive factors in AML necessitates an expanded series of genes, due to the dynamic interactions present between concurrent mutations. Hence, the current study aims to describe the benefits of an expanded risk profile in an unselected cohort of AML cases.

Figure 10.1016/j.prp.2016.02.004.0.jpg
Figure 10.1016/j.prp.2016.02.004.1.jpg
Figure 10.1016/j.prp.2016.02.004.2.jpg
Figure 10.1016/j.prp.2016.02.004.3.jpg
Figure 10.1016/j.prp.2016.02.004.4.jpg